FTH
Price
$8.80Alerts
Change
-$0.48 (-5.17%)
Updated
Nov 17, 11:46 AM (EDT)
Capitalization
569.78M
135 days until earnings call
Intraday BUY SELL Signals
IBRX
Price
$6.26Alerts
Change
+$0.28 (+4.68%)
Updated
Nov 17, 04:59 PM (EDT)
Capitalization
9.15B
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FTH vs IBRX

FTH vs IBRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
FTH vs. IBRX commentary
Nov 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FTH is a Buy and IBRX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for FTH with price predictions
Nov 16, 2026

FTH's Stochastic Oscillator remains in oversold zone for 3 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +5.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTH advanced for three days, in 168 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

FTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FTH as a result. In 89 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for FTH turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 45 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 50-day moving average for FTH moved below the 200-day moving average on November 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for FTH entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. FTH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.294) is normal, around the industry mean (3.586). P/E Ratio (-0.362) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for IBRX with price predictions
Nov 16, 2026

IBRX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 12, 2026

IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 33 cases where IBRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +12.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 212 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 84 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 46 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

IBRX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for IBRX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.744) is normal, around the industry mean (3.586). P/E Ratio (-9.089) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IBRX: Fundamental Ratings
IBRX
OUTLOOK RATING
1..100
52
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
57
P/E GROWTH RATING
1..100
66
SEASONALITY SCORE
1..100
47

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FTHIBRX
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 14 days ago
87%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
COMPARISON
Comparison
Nov 17, 2026
Stock price -- (FTH: $9.28 vs. IBRX: $5.98)
Brand notoriety: FTH and IBRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FTH: 130% vs. IBRX: 88%
Market capitalization -- FTH: $569.78M vs. IBRX: $9.15B
FTH [@Biotechnology] is valued at $569.78M. IBRX’s [@Biotechnology] market capitalization is $9.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FTH’s FA Score shows that 1 FA rating(s) are green while IBRX’s FA Score has 1 green FA rating(s).

  • FTH’s FA Score: 1 green, 4 red.
  • IBRX’s FA Score: 1 green, 4 red.
According to our system of comparison, IBRX is a better buy in the long-term than FTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FTH’s TA Score shows that 4 TA indicator(s) are bullish while IBRX’s TA Score has 4 bullish TA indicator(s).

  • FTH’s TA Score: 4 bullish, 5 bearish.
  • IBRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, FTH is a better buy in the short-term than IBRX.

Price Growth

FTH (@Biotechnology) experienced а -26.81% price change this week, while IBRX (@Biotechnology) price change was -15.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.73%. For the same industry, the average monthly price growth was -7.91%, and the average quarterly price growth was -21.89%.

Reported Earning Dates

FTH is expected to report earnings on Apr 01, 2027.

IBRX is expected to report earnings on Mar 02, 2027.

Industries' Descriptions

@Biotechnology (-9.73% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

FTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, FTH has been loosely correlated with VSTM. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if FTH jumps, then VSTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FTH
1D Price
Change %
FTH100%
-7.48%
VSTM - FTH
47%
Loosely correlated
-5.87%
ALZN - FTH
40%
Loosely correlated
-4.84%
MOLN - FTH
39%
Loosely correlated
-4.30%
ZURA - FTH
38%
Loosely correlated
-12.90%
IBRX - FTH
37%
Loosely correlated
-0.66%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TLK11.730.06
+0.51%
PT Telekomunikasi Indonesia
GLAD19.15-0.26
-1.34%
Gladstone Capital Corp
CTOS9.69-0.31
-3.10%
Custom Truck One Source
NTRB5.81-0.29
-4.75%
Nutriband
EDBL0.51-0.11
-17.74%
Edible Garden AG Incorporated